


CLAIMS

WHAT IS CLAIMED IS:

1. A compound represented by Formula (A):



Formula (A)

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 and R^2 are each independently selected from hydrogen, and substituted or unsubstituted alkyl;

R^3 is selected from substituted or unsubstituted phenyl, and substituted or unsubstituted heteroaryl, wherein if R^3 is substituted then R^3 is substituted with one or more groups selected from halogen, -CN, -OH, C_1 - C_4 alkyl, C_2 - C_4 alkenyl, C_2 - C_4 alkynyl, C_1 - C_4 alkoxy, C_1 - C_4 fluoroalkyl, C_1 - C_4 fluoroalkoxy, and substituted or unsubstituted C_1 - C_4 heteroalkyl;

R^4 is substituted or unsubstituted alkyl;

R^6 is hydrogen or substituted or unsubstituted alkyl;

or R^4 and R^6 are taken together with the carbon atom to which they are attached to form a carbonyl (C=O);

or R^4 and R^6 are taken together with the carbon atom to which they are attached to form a ring that is a substituted or unsubstituted C_3 - C_{10} cycloalkyl, or substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, wherein if the ring is substituted then it is substituted with one or more R^{15} ;

R^{15} is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted heteroaryl, -alkyl-(substituted or unsubstituted phenyl), -alkyl-(substituted or unsubstituted heteroaryl), -C(=O) R^{16} , -C(=O)-OR¹⁶, -C(=O)N(R^{16})₂;

each R^{16} is independently selected from hydrogen and substituted or unsubstituted alkyl;

R^5 is hydrogen, R^7 , -C(=O) R^7 , -C(=O)-OR⁷, -C(=O)N(R^7)(R^8), -C(=O)-SR⁷, or -P(=O)(OR⁹)₂;

or R^4 and R^5 are taken together with the atoms to which they are attached to form a substituted or unsubstituted C_2 - C_{10} heterocycloalkyl;

R^7 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted C_3 - C_{10} cycloalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted heteroaryl, -alkyl-(substituted or unsubstituted phenyl), -alkyl-(substituted or unsubstituted heteroaryl), -alkyl-(substituted or unsubstituted cycloalkyl), -alkyl-(substituted or unsubstituted heterocycloalkyl), $-(C(R^{10})_2O)_m-R^{11}$, $-(CH_2CH_2O)_n-R^{11}$, or $-(C(R^{10})_2)_p-OR^{11}$;

R^8 is hydrogen or alkyl;

or R^7 and R^8 are taken together with the nitrogen atom to which they are attached to form a substituted or unsubstituted C_2 - C_{10} heterocycloalkyl;

each R^9 is independently selected from hydrogen and alkyl;

each R^{10} is independently selected from hydrogen and alkyl;

R^{11} is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, $-C(=O)R^{12}$, $-C(=O)-OR^{12}$, $-C(=O)N(R^{12})(R^8)$, $-C(=O)-SR^{12}$, or $-P(=O)(OR^9)_2$;

R^{12} is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted C_3 - C_{10} cycloalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted heteroaryl, -alkyl-(substituted or unsubstituted phenyl), or -alkyl-(substituted or unsubstituted heteroaryl);

m is 1, 2, 3, 4, 5, or 6;

n is 1, 2, 3, 4, 5, or 6;

p is 1, 2, 3, 4, 5, or 6;

wherein substituted means that the referenced group is substituted with one or more additional groups individually and independently selected from halogen, -CN, $-NH_2$, $-NH(alkyl)$, $-N(alkyl)_2$, -OH, $-CO_2H$, $-CO_2alkyl$, $-C(=O)NH_2$, $-C(=O)NH(alkyl)$, $-C(=O)N(alkyl)_2$, $-S(=O)_2NH_2$, $-S(=O)_2NH(alkyl)$, $-S(=O)_2N(alkyl)_2$, alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, heterocycloalkyl, aryl, heteroaryl, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone.


2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^4 is C_1 - C_6 alkyl;

R^6 is selected from hydrogen, and C_1 - C_6 alkyl;

or R⁴ and R⁶ are taken together with the carbon atom to which they are attached to form a carbonyl (C=O).


3. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein:
R⁴ is methyl, ethyl, or n-propyl;
R⁶ is selected from hydrogen, methyl, ethyl, and n-propyl;
or R⁴ and R⁶ are taken together with the carbon atom to which they are attached to form a carbonyl (C=O).
4. The compound of claim 3, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has the following structure of Formula (III):



Formula (III)

or a pharmaceutically acceptable salt or solvate thereof.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein:
R¹ and R² are each independently selected from substituted or unsubstituted C₁-C₆alkyl;
R³ is selected from substituted or unsubstituted phenyl.
6. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein:
R¹ and R² are each independently selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, tert-pentyl, neopentyl, isopentyl, sec-pentyl, 3-pentyl, n-hexyl, isohexyl, 3-methylpentyl, 2,3-dimethylbutyl, and neoheptyl.
7. The compound of claim 6, or a pharmaceutically acceptable salt or solvate thereof, wherein:
R¹ is ethyl;
R² is n-propyl; and
R³ is 3-(trifluoromethyl)phenyl.
8. The compound of claim 4, wherein the compound has the following structure:



or a pharmaceutically acceptable salt or solvate thereof.

9. The compound of claim 8, or a pharmaceutically acceptable salt or solvate thereof, wherein: R^5 is R^7 ;

R^7 is C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 heteroalkyl, substituted or unsubstituted monocyclic C_3 - C_8 cycloalkyl, substituted or unsubstituted bicyclic C_5 - C_{10} cycloalkyl, substituted or unsubstituted monocyclic C_2 - C_8 heterocycloalkyl, substituted or unsubstituted bicyclic C_5 - C_{10} heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted monocyclic heteroaryl, $-CH_2$ -(substituted or unsubstituted phenyl), $-CH_2$ -(substituted or unsubstituted heteroaryl), $-CH_2$ -(substituted or unsubstituted C_2 - C_8 heterocycloalkyl), $-CH(R^{10})O-R^{11}$, $-(CH_2CH_2O)_n-R^{11}$, or $-(C(R^{10})_2)_p-OR^{11}$;

each R^{10} is independently selected from hydrogen and methyl;


R^{11} is hydrogen, C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 heteroalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, $-C(=O)R^{12}$, $-C(=O)-OR^{12}$, $-C(=O)N(R^{12})(R^8)$, $-C(=O)-SR^{12}$, or $-P(=O)(OR^9)_2$.

10. The compound of claim 9, or a pharmaceutically acceptable salt or solvate thereof, wherein: R^7 is C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 heteroalkyl, $-CH_2$ -(substituted or unsubstituted phenyl), $-CH_2$ -(substituted or unsubstituted heteroaryl), $-CH_2$ -(substituted or unsubstituted C_2 - C_8 heterocycloalkyl), $-CH(R^{10})O-R^{11}$, or $-(CH_2CH_2O)_n-R^{11}$;

R^{10} is hydrogen and methyl;


R^{11} is hydrogen, C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 heteroalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, $-C(=O)R^{12}$, $-C(=O)-OR^{12}$, $-C(=O)N(R^{12})(R^8)$, $-C(=O)-SR^{12}$, or $-P(=O)(OH)_2$.

11. The compound of claim 10, wherein the compound has one of the following structures:




or a pharmaceutically acceptable salt or solvate thereof.

12. The compound of claim 8, wherein the compound has one of the following structures:



or a pharmaceutically acceptable salt or solvate thereof.


13. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has the following structure of Formula (I):



Formula (I)

or a pharmaceutically acceptable salt or solvate thereof.

14. The compound of claim 13, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^1 and R^2 are each independently selected from substituted or unsubstituted C_1 - C_6 alkyl;
 R^3 is selected from substituted or unsubstituted phenyl.
15. The compound of claim 13, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^1 is ethyl;
 R^2 is n-propyl; and
 R^3 is 3-(trifluoromethyl)phenyl.
16. The compound of claim 13, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has the following structure:



or a pharmaceutically acceptable salt or solvate thereof.

17. The compound of claim 16, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^4 is methyl or ethyl;
 R^5 is hydrogen, R^7 , $-C(=O)R^7$, $-C(=O)OR^7$, $-C(=O)N(R^7)(R^8)$, $-C(=O)SR^7$, or $-P(=O)(OR^9)_2$;

R^7 is C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 heteroalkyl, substituted or unsubstituted monocyclic C_3 - C_8 cycloalkyl, substituted or unsubstituted bicyclic C_5 - C_{10} cycloalkyl, substituted or unsubstituted monocyclic C_2 - C_8 heterocycloalkyl, substituted or unsubstituted bicyclic C_5 - C_{10} heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted monocyclic heteroaryl, $-\text{CH}_2$ -(substituted or unsubstituted phenyl), $-\text{CH}_2$ -(substituted or unsubstituted heteroaryl), $-\text{CH}_2$ -(substituted or unsubstituted C_2 - C_8 heterocycloalkyl), $-\text{CH}(R^{10})\text{O}-R^{11}$, $-(\text{CH}_2\text{CH}_2\text{O})_n-R^{11}$, or $-(C(R^{10})_2)_p\text{OR}^{11}$;

each R^{10} is independently selected from hydrogen and methyl;

R^{11} is hydrogen, C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 heteroalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, $-\text{C}(=\text{O})R^{12}$, $-\text{C}(=\text{O})-\text{OR}^{12}$, $-\text{C}(=\text{O})\text{N}(R^{12})(R^8)$, $-\text{C}(=\text{O})-\text{SR}^{12}$, or $-\text{P}(=\text{O})(\text{OR}^9)_2$.

18. The compound of claim 16, or a pharmaceutically acceptable salt or solvate thereof, wherein:


R^5 is R^7 , $-\text{C}(=\text{O})R^7$, $-\text{C}(=\text{O})-\text{OR}^7$, $-\text{C}(=\text{O})\text{N}(R^7)(R^8)$, $-\text{C}(=\text{O})-\text{SR}^7$, or $-\text{P}(=\text{O})(\text{OH})_2$;


R^7 is C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 heteroalkyl, substituted or unsubstituted cyclohexyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted bicyclo[1.1.1]pentanyl, substituted or unsubstituted bicyclo[2.2.1]heptanyl, substituted or unsubstituted bicyclo[2.2.2]octanyl, substituted or unsubstituted bicyclo[3.2.1]octanyl, substituted or unsubstituted bicyclo[3.3.0]octanyl, substituted or unsubstituted bicyclo[4.3.0]nonanyl, or substituted or unsubstituted decanyl, substituted or unsubstituted oxetanyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted azetidyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted piperidinyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted thiomorpholinyl, substituted or unsubstituted phenyl, substituted or unsubstituted monocyclic heteroaryl, $-\text{CH}_2$ -(substituted or unsubstituted phenyl), $-\text{CH}_2$ -(substituted or unsubstituted heteroaryl), $-\text{CH}_2$ -(substituted or unsubstituted C_2 - C_8 heterocycloalkyl), $-\text{CH}(R^{10})\text{O}-R^{11}$, $-(\text{CH}_2\text{CH}_2\text{O})_n-R^{11}$, or $-(C(R^{10})_2)_p\text{OR}^{11}$;

each R^{10} is independently selected from hydrogen and methyl;

R^{11} is hydrogen, C_1 - C_6 alkyl, substituted or unsubstituted C_1 - C_6 heteroalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, $-\text{C}(=\text{O})R^{12}$, $-\text{C}(=\text{O})-\text{OR}^{12}$, $-\text{C}(=\text{O})\text{N}(R^{12})(R^8)$, $-\text{C}(=\text{O})-\text{SR}^{12}$, or $-\text{P}(=\text{O})(\text{OR}^9)_2$.


19. The compound of claim 16, wherein the compound has one of the following structures:





or a pharmaceutically acceptable salt or solvate thereof.

20. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has the following structure of Formula (II):



Formula (II)

wherein:

Y is selected from $-\text{CH}_2-$, O, S, $-\text{NR}^{15}$ -, and $-\text{S}(\text{O})_2-$;

Z is O or S;

or a pharmaceutically acceptable salt or solvate thereof.

21. The compound of claim 20, or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 and R^2 are each independently selected from substituted or unsubstituted C_1 - C_6 alkyl;
 R^3 is selected from substituted or unsubstituted phenyl.


22. The compound of claim 20, or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 is ethyl;

R^2 is n-propyl; and


R^3 is 3-(trifluoromethyl)phenyl.

23. The compound of claim 20, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has the following structure:




or a pharmaceutically acceptable salt or solvate thereof.

24. The compound of claim 1, wherein the compound has the following structure:



or a pharmaceutically acceptable salt or solvate thereof.

25. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound has the following structure of Formula (IIa):




Formula (IIa)

wherein:


Y is selected from $-\text{CH}_2-$, O, S, $-\text{NR}^{15}-$, and $-\text{S}(\text{O})_2-$;
or a pharmaceutically acceptable salt or solvate thereof.

26. The compound of claim 25, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^1 and R^2 are each independently selected from substituted or unsubstituted C_1 - C_6 alkyl;
 R^3 is selected from substituted or unsubstituted phenyl.
27. The compound of claim 25, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^1 is ethyl;
 R^2 is n-propyl; and
 R^3 is 3-(trifluoromethyl)phenyl.
28. The compound of claim 25, wherein the compound has the following structure:



or a pharmaceutically acceptable salt or solvate thereof.

29. A compound represented by Formula (B):



Formula (B)

or a pharmaceutically acceptable salt or solvate thereof, wherein:

- R^1 and R^2 are each independently selected from hydrogen, and substituted or unsubstituted alkyl;
 R^3 is selected from substituted or unsubstituted phenyl, and substituted or unsubstituted heteroaryl, wherein if R^3 is substituted then R^3 is substituted with one or more groups selected from halogen, $-\text{CN}$, $-\text{OH}$, C_1 - C_4 alkyl, C_2 - C_4 alkenyl, C_2 - C_4 alkynyl, C_1 -

C₄alkoxy, C₁-C₄fluoroalkyl, C₁-C₄fluoroalkoxy, and substituted or unsubstituted C₁-C₄heteroalkyl;

R⁴ is hydrogen or substituted or unsubstituted alkyl;

R⁶ is hydrogen or substituted or unsubstituted alkyl;

or R⁴ and R⁶ are taken together with the carbon atom to which they are attached to form a carbonyl (C=O);

or R⁴ and R⁶ are taken together with the carbon atom to which they are attached to form a ring that is a substituted or unsubstituted C₃-C₁₀cycloalkyl, or substituted or unsubstituted C₂-C₁₀heterocycloalkyl, wherein if the ring is substituted then it is substituted with one or more R¹⁵;

R¹⁵ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted heteroaryl, -alkyl-(substituted or unsubstituted phenyl), -alkyl-(substituted or unsubstituted heteroaryl), -C(=O)R¹⁶, -C(=O)-OR¹⁶, -C(=O)N(R¹⁶)₂;

each R¹⁶ is independently selected from hydrogen and substituted or unsubstituted alkyl;

R⁵ is substituted or unsubstituted C₃-C₁₀cycloalkyl, substituted or unsubstituted C₂-C₁₀heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted heteroaryl, -alkyl-(substituted or unsubstituted phenyl), -alkyl-(substituted or unsubstituted heteroaryl), -alkyl-(substituted or unsubstituted cycloalkyl), -alkyl-(substituted or unsubstituted heterocycloalkyl), -(C(R¹⁰)₂O)_m-R¹¹, -C(=O)-(C(R¹⁰)₂O)_m-R¹¹, -C(=O)-(CH₂CH₂O)_n-R¹¹, -C(=O)-R^a or -C(=O)-OR⁷;

R^a is substituted or unsubstituted bicyclic cycloalkyl, substituted or unsubstituted bicyclic heterocycloalkyl, substituted or unsubstituted bicyclic heteroaryl, (substituted or unsubstituted heterocycloalkyl containing at least one O atom in the ring), substituted or unsubstituted azetidiny, substituted or unsubstituted piperidiny, substituted or unsubstituted azapenyl, substituted or unsubstituted 5-membered heteroaryl, substituted or unsubstituted pyridin-2-yl, substituted or unsubstituted pyridin-4-yl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted triazinyl;

or R⁴ and R⁵ are taken together with the atoms to which they are attached to form a substituted or unsubstituted C₂-C₁₀heterocycloalkyl;

R⁷ is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted C₃-C₁₀cycloalkyl, substituted or unsubstituted C₂-C₁₀heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted heteroaryl, -alkyl-

(substituted or unsubstituted phenyl), -alkyl-(substituted or unsubstituted heteroaryl), -alkyl-(substituted or unsubstituted cycloalkyl), -alkyl-(substituted or unsubstituted heterocycloalkyl), $-(C(R^{10})_2O)_m-R^{11}$, $-(CH_2CH_2O)_n-R^{11}$, or $-(C(R^{10})_2)_p-OR^{11}$,
 each R^9 is independently selected from hydrogen and alkyl;
 each R^{10} is independently selected from hydrogen and alkyl;
 R^{11} is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, $-C(=O)R^{12}$, $-C(=O)-OR^{12}$, $-C(=O)N(R^{12})(R^8)$, $-C(=O)-SR^{12}$, or $-P(=O)(OR^9)_2$;
 R^{12} is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted C_3 - C_{10} cycloalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted heteroaryl, -alkyl-(substituted or unsubstituted phenyl), or -alkyl-(substituted or unsubstituted heteroaryl);
 m is 1, 2, 3, 4, 5, or 6;
 n is 1, 2, 3, 4, 5, or 6;
 p is 1, 2, 3, 4, 5, or 6;
 wherein substituted means that the referenced group is substituted with one or more additional groups individually and independently selected from halogen, -CN, $-NH_2$, -NH(alkyl), $-N(alkyl)_2$, -OH, $-CO_2H$, $-CO_2alkyl$, $-C(=O)NH_2$, $-C(=O)NH(alkyl)$, $-C(=O)N(alkyl)_2$, $-S(=O)_2NH_2$, $-S(=O)_2NH(alkyl)$, $-S(=O)_2N(alkyl)_2$, alkyl, cycloalkyl, fluoroalkyl, heteroalkyl, alkoxy, fluoroalkoxy, heterocycloalkyl, aryl, heteroaryl, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, and arylsulfone.

30. The compound of claim 29, or a pharmaceutically acceptable salt or solvate thereof, wherein:
 R^4 is hydrogen;
 R^6 is hydrogen;
 R^5 is substituted or unsubstituted C_3 - C_{10} cycloalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted heteroaryl, -alkyl-(substituted or unsubstituted phenyl), -alkyl-(substituted or unsubstituted heteroaryl), -alkyl-(substituted or unsubstituted cycloalkyl), -alkyl-(substituted or unsubstituted heterocycloalkyl), $-(C(R^{10})_2O)_m-R^{11}$, $-C(=O)-(C(R^{10})_2O)_m-R^{11}$, $-C(=O)-(CH_2CH_2O)_n-R^{11}$, $-C(=O)-R^a$ or $-C(=O)-OR^7$.
31. The compound of claim 29 or claim 30, or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 and R^2 are each independently selected from substituted or unsubstituted C_1 - C_6 alkyl;
 R^3 is selected from substituted or unsubstituted phenyl.

32. The compound of claim 29 or claim 30, or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 and R^2 are each independently selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, tert-pentyl, neopentyl, isopentyl, sec-pentyl, 3-pentyl, n-hexyl, isohexyl, 3-methylpentyl, 2,3-dimethylbutyl, and neoheptyl.


33. The compound of claim 29 or claim 30, or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^1 is ethyl;

R^2 is n-propyl; and

R^3 is 3-(trifluoromethyl)phenyl.

34. The compound of claim 29 or claim 30, wherein the compound has the following structure:




or a pharmaceutically acceptable salt or solvate thereof.

35. The compound of claim 34, or a pharmaceutically acceptable salt or solvate thereof, wherein:


R^{11} is hydrogen, substituted or unsubstituted alkyl, $-C(=O)R^{12}$, $-C(=O)-OR^{12}$, $-C(=O)N(R^{12})(R^8)$, or $-P(=O)(OR^9)_2$.

36. The compound of claim 35, wherein the compound has one of the following structures:



or a pharmaceutically acceptable salt or solvate thereof.

37. The compound of claim 35, wherein the compound has one of the following structures:




or a pharmaceutically acceptable salt or solvate thereof.

38. The compound of claim 29 or claim 30, or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^5 is $-C(=O)-(C(R^{10})_2O)_m-R^{11}$, $-C(=O)-(CH_2CH_2O)_n-R^{11}$, $-C(=O)-R^a$ or $-C(=O)-OR^7$.

39. The compound of claim 38, wherein the compound has the following structure:



or a pharmaceutically acceptable salt or solvate thereof.

40. The compound of claim 39, or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^a is substituted or unsubstituted bicyclic cycloalkyl that is a fused bicyclic cycloalkyl, bridged bicyclic cycloalkyl, or spiro bicyclic cycloalkyl;


or R^a is substituted or unsubstituted bicyclic heterocycloalkyl that is a fused bicyclic heterocycloalkyl, bridged bicyclic heterocycloalkyl, or spiro bicyclic heterocycloalkyl;

or R^a is substituted or unsubstituted bicyclic heteroaryl.

41. The compound of claim 39, or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^a is substituted or unsubstituted bicyclo[1.1.1]pentanyl, substituted or unsubstituted bicyclo[2.2.1]heptanyl, substituted or unsubstituted bicyclo[2.2.2]octanyl, substituted or unsubstituted bicyclo[3.2.1]octanyl, substituted or unsubstituted bicyclo[3.3.0]octanyl, substituted or unsubstituted bicyclo[4.3.0]nonanyl, or substituted or unsubstituted decalanyl.

42. The compound of claim 40, wherein the compound has one of the following structures:



or a pharmaceutically acceptable salt or solvate thereof.

43. The compound of claim 39, or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^a is substituted or unsubstituted heterocycloalkyl containing at least one O atom in the ring, substituted or unsubstituted azetidiny, substituted or unsubstituted piperidiny, substituted or unsubstituted azapenyl, substituted or unsubstituted 5-membered heteroaryl, substituted or unsubstituted pyridin-2-yl, substituted or unsubstituted pyridin-4-yl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyrazinyl, substituted or unsubstituted pyridazinyl, substituted or unsubstituted triazinyl.

44. The compound of claim 43, or a pharmaceutically acceptable salt or solvate thereof, wherein:


R^a is a substituted or unsubstituted heterocycloalkyl containing at least one O atom in the ring that is substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted dihydrofuranyl, substituted or unsubstituted oxazolidinonyl, substituted or unsubstituted tetrahydropyranyl, substituted or unsubstituted dihydropyranyl, substituted or unsubstituted tetrahydrothiopyranyl, substituted or unsubstituted morpholinyl, substituted or unsubstituted oxetanyl, substituted or unsubstituted oxepanyl, substituted or unsubstituted oxazepinyl, or substituted or unsubstituted dioxanyl.

45. The compound of claim 43, or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^a is a substituted or unsubstituted 5-membered heteroaryl that is substituted or unsubstituted furanyl, substituted or unsubstituted thienyl, substituted or unsubstituted

pyrrolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl, substituted or unsubstituted triazolyl, substituted or unsubstituted tetrazolyl, substituted or unsubstituted isoxazolyl, substituted or unsubstituted isothiazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted thiadiazolyl,

46. The compound of claim 43, wherein the compound has one of the following structures:



or a pharmaceutically acceptable salt or solvate thereof.

47. The compound of claim 29 or claim 30, or a pharmaceutically acceptable salt or solvate thereof, wherein:


R¹ is ethyl;

R^2 is n-propyl;

R^3 is 3-(trifluoromethyl)phenyl;

R^5 is $-C(=O)-(C(R^{10})_2O)_m-R^{11}$, $-C(=O)-(CH_2CH_2O)_n-R^{11}$, or $-C(=O)-OR^7$.

48. The compound of claim 47, wherein the compound has one of the following structures:



or a pharmaceutically acceptable salt or solvate thereof.

49. The compound of claim 29 or claim 30, or a pharmaceutically acceptable salt or solvate thereof, wherein:


R^1 is ethyl;

R^2 is n-propyl;

R^3 is 3-(trifluoromethyl)phenyl;

R^5 is substituted or unsubstituted C_3 - C_{10} cycloalkyl, substituted or unsubstituted C_2 - C_{10} heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted heteroaryl, -alkyl-(substituted or unsubstituted phenyl), -alkyl-(substituted or unsubstituted heteroaryl), -alkyl-(substituted or unsubstituted cycloalkyl), -alkyl-(substituted or unsubstituted heterocycloalkyl).

50. The compound of claim 49, wherein the compound has the following structure:



or a pharmaceutically acceptable salt or solvate thereof.

51. A pharmaceutical formulation, comprising a compound of any one of claims 1-50, or any pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

52. The pharmaceutical composition of claim 51, wherein the pharmaceutical composition is formulated for administration to a mammal by oral administration, intravenous administration, or subcutaneous administration.
53. The pharmaceutical composition of claim 51, wherein the pharmaceutical composition is in the form of a tablet, a pill, a capsule, a liquid, a suspension, a dispersion, a solution, or an emulsion.
54. A method of modulating the A_{2B} adenosine receptor in a mammal comprising administering to the mammal a compound of any one of claims 1-50, or any pharmaceutically acceptable salt or solvate thereof.
55. A method of treating a disease or disorder in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound of any one of claims 1-50, or a pharmaceutically acceptable salt or solvate thereof, wherein the condition is selected from the group consisting of cardiovascular diseases, fibrosis, neurological disorders, type I hypersensitivity disorders, chronic and acute liver diseases, lung diseases, renal diseases, diabetes, obesity, and cancer.
56. The method of claim 55, wherein the condition is cancer.
57. The method of any one of claims 54-56, wherein the subject is human.